Prescient doses first patient in Phase 2a cancer trial
The first patient has been dosed in Prescient Therapeutics Phase 2a clinical trial of PTX-100...
The first patient has been dosed in Prescient Therapeutics Phase 2a clinical trial of PTX-100...
Cell and gene therapy is changing the game when it comes to cancer treatment and...
CAR-T therapy is leading the race as the holy grail to cure cancer but like...
Prescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatment and...
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.